Paul D Morrison - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Paul D Morrison

Showing results (71-80 of 73) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 73 results.

The Lancet. Psychiatry|August 1, 2020

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trialTom P Freeman, Chandni Hindocha, Gianluca Baio, et al.

Schizophrenia Bulletin|July 18, 2014

How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoiaDaniel Freeman, Graham Dunn, Robin M Murray, et al.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 20, 2009

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathologySagnik Bhattacharyya, Paul D Morrison, Paolo Fusar-Poli, et al.

Pageof 8

Search research articles

Showing results (71-80 of 73) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 73 results.

The Lancet. Psychiatry|August 1, 2020

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trialTom P Freeman, Chandni Hindocha, Gianluca Baio, et al.

Schizophrenia Bulletin|July 18, 2014

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 20, 2009

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathologySagnik Bhattacharyya, Paul D Morrison, Paolo Fusar-Poli, et al.

Pageof 8